Články se zplnomocněním k veřejnému přístupu - Doruk ErkanDalší informace
Nedostupné nikde: 10
Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: a critical review of the …
L Andreoli, CB Chighizola, A Banzato, GJ Pons‐Estel, GR de Jesus, ...
Arthritis care & research 65 (11), 1869-1873, 2013
Zplnomocnění: Government of Italy
14th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends
D Erkan, CL Aguiar, D Andrade, H Cohen, MJ Cuadrado, A Danowski, ...
Autoimmunity reviews 13 (6), 685-696, 2014
Zplnomocnění: Versus Arthritis, UK
Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: a systematic review and meta-analysis
S Zuily, V Domingues, C Suty-Selton, V Eschwège, L Bertoletti, A Chaouat, ...
Autoimmunity Reviews 16 (6), 576-586, 2017
Zplnomocnění: US National Institutes of Health
Treatment of antiphospholipid syndrome beyond anticoagulation
C Dobrowolski, D Erkan
Clinical Immunology 206, 53-62, 2019
Zplnomocnění: US National Institutes of Health
Expert perspective: management of microvascular and catastrophic antiphospholipid syndrome
D Erkan
Arthritis & Rheumatology 73 (10), 1780-1790, 2021
Zplnomocnění: US National Institutes of Health
Efforts to better characterize “antiphospholipid antibody nephropathy” for the 2023 ACR/EULAR Antiphospholipid Syndrome Classification criteria: Renal Pathology Subcommittee report
M Barbhaiya, M Taghavi, S Zuily, V Domingues, EY Chock, ...
The Journal of Rheumatology 51 (2), 150-159, 2024
Zplnomocnění: National Institute of Health and Medical Research, France
16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome
S Sciascia, M Radin, I Cecchi, RA Levy, D Erkan
Lupus 30 (8), 1314-1326, 2021
Zplnomocnění: Government of Italy
AntiPhospholipid syndrome alliance for clinical trials and International networking (APS ACTION): 5-year update
M Barbhaiya, D Andrade, D Erkan, APS ACTION
Current rheumatology reports 18, 1-7, 2016
Zplnomocnění: US National Institutes of Health
Mammalian target of rapamycin pathway assessment in antiphospholipid antibody–positive patients with livedo
E Sevim, S Siddique, MLS Chalasani, S Chyou, WD Shipman, O O’Shea, ...
The Journal of Rheumatology 49 (9), 1026-1030, 2022
Zplnomocnění: US National Institutes of Health
Immunosuppression use in primary antiphospholipid antibody-positive patients: Descriptive analysis of the AntiPhospholipid Syndrome Alliance for Clinical Trials and …
ZB Erton, R K Leaf, D de Andrade, AE Clarke, MG Tektonidou, V Pengo, ...
Lupus 31 (14), 1770-1776, 2022
Zplnomocnění: US National Institutes of Health
Dostupné někde: 42
Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications
JT Merrill, D Erkan, J Winakur, JA James
Nature Reviews Rheumatology 16 (10), 581-589, 2020
Zplnomocnění: US National Institutes of Health
Pathogenic autoreactive T and B cells cross-react with mimotopes expressed by a common human gut commensal to trigger autoimmunity
WE Ruff, C Dehner, WJ Kim, O Pagovich, CL Aguiar, TY Andrew, AS Roth, ...
Cell host & microbe 26 (1), 100-113. e8, 2019
Zplnomocnění: US National Institutes of Health, American Heart Association
A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients
D Erkan, R Willis, VL Murthy, G Basra, JA Vega, P Ruiz-Limón, AL Carrera, ...
Annals of the rheumatic diseases 73 (6), 1176-1180, 2014
Zplnomocnění: US National Institutes of Health
The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: results from the APS ACTION cohort
M Radin, S Sciascia, D Erkan, V Pengo, MG Tektonidou, A Ugarte, ...
Seminars in arthritis and rheumatism 49 (3), 464-468, 2019
Zplnomocnění: US National Institutes of Health
The effect of triple therapy on the mortality of catastrophic anti-phospholipid syndrome patients
I Rodríguez-Pintó, G Espinosa, D Erkan, Y Shoenfeld, R Cervera
Rheumatology 57 (7), 1264-1270, 2018
Zplnomocnění: US National Institutes of Health
16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends
H Cohen, MJ Cuadrado, D Erkan, A Duarte-Garcia, DA Isenberg, ...
Lupus 29 (12), 1571-1593, 2020
Zplnomocnění: UK Medical Research Council
Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria
M Barbhaiya, S Zuily, Y Ahmadzadeh, MC Amigo, T Avcin, ...
Arthritis care & research 73 (10), 1490-1501, 2021
Zplnomocnění: US National Institutes of Health, British Heart Foundation
Aps action–antiphospholipid syndrome alliance for clinical trials and international networking
D Erkan, MD Lockshin
Lupus 21 (7), 695-698, 2012
Zplnomocnění: US National Institutes of Health
Antiphospholipid syndrome treatment beyond anticoagulation: are we there yet?
SS Pierangeli, D Erkan
Lupus 19 (4), 475-485, 2010
Zplnomocnění: US National Institutes of Health
Hydroxychloroquine in the primary thrombosis prophylaxis of antiphospholipid antibody positive patients without systemic autoimmune disease
D Erkan, O Unlu, S Sciascia, HM Belmont, DW Branch, MJ Cuadrado, ...
Lupus 27 (3), 399-406, 2018
Zplnomocnění: US National Institutes of Health
Informace o publikování a financování jsou automaticky vybírány počítačovým programem